Key result
E-4031 increased the overall right atrial effective refractory period from 210 ms to 232 ms and decreased the incidence of repetitive atrial firing.
Why the study?
Does the class III antiarrhythmic agent E-4031 alter electrophysiological properties such as refractoriness and conduction in human atrial muscle in vivo?
Does the class III antiarrhythmic agent E-4031 alter electrophysiological properties such as refractoriness and conduction in human atrial muscle in vivo?
E-4031 prolongs the atrial effective refractory period and reduces repetitive atrial firing, suggesting potential efficacy for treating paroxysmal atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support E-4031 testing in paroxysmal AF; hypothesis-generating and requires randomized confirmation.
OBJECTIVE: The aim was to test the efficacy of a new class III drug, E-4031, on human atrial muscle in vivo. METHODS: Electrophysiological measurements were performed in 10 patients, age 54(SD 11) years, before and during the continuous infusion of E-4031 (0.15 microgram.kg-1.min-1) which followed an initial dose of 9 micrograms.kg-1 x 5 min-1. Extrastimuli at 500 ms were delivered from the right atrial appendage, high lateral right atrium, and low lateral right atrium. The effective refractory period, repetitive atrial firing zone, and fragmented atrial activity zone were assessed at three sites in the right atrium. The conduction delay zone from the stimulus artefact to the distal electrode pair at the coronary sinus was also measured. RESULTS: E-4031 caused a significant increase in overall right atrial effective refractory period from 210(SD 29) to 232(26) ms (p < 0.001, n = 30 sites). There were significant decreases in the incidence of repetitive atrial firing (67% to 37%: p < 0.005), in the repetitive atrial firing zone [23(20) to 11(22) ms: p < 0.01], and in the fragmented atrial activity zone [15(22) to 3(8) ms: p < 0.005], but no significant change in the conduction delay zone. However, E-4031 significantly prolonged the longest coupling interval that elicited conduction delay, from 249(31) ms to 267(28) ms (p < 0.01). E-4031 had no effect on the conduction time except at coupling intervals close to the atrial effective refractory period. CONCLUSION: These results suggest that E-4031 has a potential effect in the treatment of human paroxysmal atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Shimizu et al. (1993) studied Paroxysmal atrial fibrillation (n=10). E-4031 vs. Baseline (before infusion) was evaluated on Overall right atrial effective refractory period (p=< 0.001). E-4031 increased the overall right atrial effective refractory period from 210 ms to 232 ms and decreased the incidence of repetitive atrial firing.
Synapse has enriched 10 related papers. Consider them for comparative context: